Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. reported an equity award to one of its directors on a Form 4 insider transaction report. On December 31, 2025, the director received 24,633 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. These options have an exercise price of $1.53 per share, vest 100% on the grant date, and are exercisable beginning December 31, 2025, through December 31, 2035. Following this grant, the director beneficially owns 24,633 derivative securities in the form of these options, held directly.
MAIA Biotechnology director Stan V. Smith reported buying additional shares and options in the company. On December 22, 2025, he purchased 57,189 shares of MAIA common stock at $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. After this transaction, he beneficially owns 1,421,478 shares indirectly through The Stan V. Smith Trust Dated 1993, plus additional indirect holdings of 4,580 shares in each of three separate family trusts.
He also acquired 57,189 stock options (described as warrants deemed options) with an exercise price of $1.36 per share. These options become exercisable on the six-month anniversary of the issuance date, June 22, 2026, and expire three years after the initial issuance date, on December 22, 2028. The filing notes that certain family-trust shares are held for relatives and that he disclaims beneficial ownership of those except to the extent of any pecuniary interest.
MAIA Biotechnology director reports stock and option purchases. A company director filed details of a recent transaction in MAIA Biotechnology, Inc. common stock. On December 22, 2025, the director purchased 40,849 shares of common stock at a price of $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. Following this transaction, the director beneficially owns 151,873 shares of MAIA common stock directly.
The director also acquired 40,849 stock options (treated as warrants under the same purchase agreement and plan) with an exercise price of $1.36 per share. These options become exercisable on June 22, 2026, which is six months after the issuance date, and are scheduled to expire on December 22, 2028.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported an insider purchase of common stock and related stock options. On 12/22/2025, the director acquired 81,699 shares of common stock at $1.224 per share pursuant to a Securities Purchase Agreement, bringing total directly held common shares to 1,248,888.
On the same date, the director also acquired stock options on 81,699 shares with an exercise price of $1.36 per share. These options, deemed options under the company’s 2021 Equity Incentive Plan, become exercisable on 06/22/2026 and expire on 12/22/2028. Following these transactions, the director beneficially owns 81,699 derivative securities in addition to the common stock holdings.
MAIA Biotechnology entered into a private placement with accredited investors and certain directors, selling 1,053,751 shares of common stock with matching warrants plus 179,737 director shares with matching warrants at a purchase price of $1.224 per share, for combined expected gross proceeds of approximately $2,253,896 before expenses.
The investor and director warrants become exercisable six months after issuance, carry an exercise price of 1.36 per share described as the Minimum Price under NYSE American Rule 713, and have three-year terms. Director securities are being issued under the company’s 2021 Equity Incentive Plan. MAIA plans to use the net proceeds to fund the starting cost for Step 1 of Part C of its Phase II trial THIO-101 and for working capital, with closing expected on December 18, 2025, subject to customary conditions.
MAIA Biotechnology filed an 8-K to highlight several corporate updates announced on December 11, 2025. The company reported that its leadership team has continued insider purchases of MAIA stock in 2025, signaling ongoing management engagement with the business. MAIA also announced that the first patient has been dosed in its THIO-104 Phase 3 pivotal trial evaluating its drug candidate Ateganosine as a third-line treatment for advanced non-small cell lung cancer. A third press release emphasized the momentum behind Ateganosine as this pivotal Phase 3 trial gets underway, underscoring MAIA’s focus on advancing its oncology pipeline.
MAIA Biotechnology filed an 8-K to highlight several corporate updates announced on December 11, 2025. The company reported that its leadership team has continued insider purchases of MAIA stock in 2025, signaling ongoing management engagement with the business. MAIA also announced that the first patient has been dosed in its THIO-104 Phase 3 pivotal trial evaluating its drug candidate Ateganosine as a third-line treatment for advanced non-small cell lung cancer. A third press release emphasized the momentum behind Ateganosine as this pivotal Phase 3 trial gets underway, underscoring MAIA’s focus on advancing its oncology pipeline.
MAIA Biotechnology filed an 8-K to highlight several corporate updates announced on December 11, 2025. The company reported that its leadership team has continued insider purchases of MAIA stock in 2025, signaling ongoing management engagement with the business. MAIA also announced that the first patient has been dosed in its THIO-104 Phase 3 pivotal trial evaluating its drug candidate Ateganosine as a third-line treatment for advanced non-small cell lung cancer. A third press release emphasized the momentum behind Ateganosine as this pivotal Phase 3 trial gets underway, underscoring MAIA’s focus on advancing its oncology pipeline.
MAIA Biotechnology, Inc. filed a current report to announce that it issued a new press release on December 10, 2025 titled “MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach.” The filing itself does not add financial results, but formally places the press release into the public record as an exhibit.
The company also includes a detailed caution about forward-looking statements, explaining that comments about its research programs, product candidates, regulatory timelines, manufacturing, market potential, and intellectual property involve risks and uncertainties that could cause actual results to differ materially. MAIA states it has no obligation to update these forward-looking statements except as required by law.
MAIA Biotechnology, Inc. director Stan V. Smith reported open-market purchases of the company’s common stock. On December 5, 2025, three separate transactions were reported, each for 4,580 shares of MAIA common stock at prices of $1.1997, $1.19, and $1.20 per share, all coded as purchases. These shares are held indirectly through three Illinois Uniform Transfers to Minors Act accounts for Mr. Smith’s family members, and he reports beneficial ownership only to the extent of his pecuniary interest.
In addition, the filing shows 1,364,289 shares of MAIA common stock beneficially owned indirectly through The Stan V. Smith Trust dated 1993. The form is filed as a single-reporting-person filing and reflects Mr. Smith’s status as a director of MAIA Biotechnology.
MAIA Biotechnology CEO Vlad Vitoc reports updated ownership of the company’s common stock. He beneficially owns 3,846,352 shares of MAIA Biotechnology, Inc. common stock, representing 9.66% of the outstanding shares, based on 39,805,300 shares outstanding as of December 2, 2025. His holdings include shares owned directly by him and his spouse, as well as shares issuable upon the exercise of stock options and warrants held by him and certain family trusts. The filing states that he acquired these shares through equity award grants under the company’s incentive plans and through open-market purchases with personal funds.
The filing notes that Vitoc holds the shares for investment purposes and may buy more or sell some in the future, or use hedging strategies, subject to applicable law. During the 60 days prior to the filing, he purchased 94,300 shares of MAIA common stock in the open market at prices generally around $1 per share on several dates in November 2025.
MAIA Biotechnology, Inc. Chief Executive Officer and director Vlad Vitoc, a more than 10% owner of the company, reported an open-market purchase of common stock. On 11/25/2025, he bought 10,500 shares of MAIA common stock at a price of $0.9661 per share. Following this transaction, he directly owned 831,421 common shares and indirectly held 210,100 common shares through his spouse.
This filing is an amendment to a prior Form 4 originally filed on 11/28/2025. The amendment corrects the previously reported total share balance owned by Mr. Vitoc’s spouse and now reflects the correct indirect ownership amount, while also reiterating that he disclaims beneficial ownership of those spouse-held shares except to the extent of his economic interest.